Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
NCT07535242 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2026-04-17
Summary
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Conditions
Sponsors & Collaborators
-
Ondokuz Mayıs University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-21
- Primary Completion
- 2026-04-30
- Completion
- 2026-05-05
More Related Trials
-
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
NCT05077956 ·Status: WITHDRAWN
-
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740 ·Status: RECRUITING
-
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
NCT04860947 ·Status: ACTIVE_NOT_RECRUITING
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
Disease Progression in ms
NCT07292116 ·Status: NOT_YET_RECRUITING
-
Baseline Cortical Haemodynamics in MS
NCT02481882 ·Status: UNKNOWN ·Phase: NA
-
Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis
NCT06546033 ·Status: RECRUITING ·Phase: NA
-
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT01310166 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis
NCT04892134 ·Status: RECRUITING
-
Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases
NCT05088473 ·Status: COMPLETED
-
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT04873492 ·Status: RECRUITING ·Phase: NA
-
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691 ·Status: RECRUITING
-
Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients
NCT07526298 ·Status: NOT_YET_RECRUITING
-
Impact of Exercise Training on Serum Glial Fibrillary Acidic Protein (GFAP), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis
NCT07521995 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Fatigue in MS: From Invisible to Measurable
NCT07182903 ·Status: COMPLETED
-
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
NCT04380220 ·Status: UNKNOWN
-
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).
NCT07546110 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
MS-ResearchBiomarkerS
NCT05204459 ·Status: RECRUITING
-
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
NCT07353216 ·Status: RECRUITING
-
Investigation of the Effect of the MIND Diet on Disease Symptoms in Patients With MS
NCT07057999 ·Status: COMPLETED ·Phase: NA
-
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631 ·Status: TERMINATED ·Phase: NA
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients
NCT01380041 ·Status: TERMINATED
-
Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients
NCT04182269 ·Status: COMPLETED
-
Progression of Cognitive and Physical Symptoms in Multiple Sclerosis
NCT00922831 ·Status: WITHDRAWN